Literature DB >> 19433579

Hemoglobin and its scavenger protein haptoglobin associate with apoA-1-containing particles and influence the inflammatory properties and function of high density lipoprotein.

Junji Watanabe1, Victor Grijalva, Susan Hama, Karen Barbour, Franklin G Berger, Mohamad Navab, Alan M Fogelman, Srinivasa T Reddy.   

Abstract

Hemoglobin (Hb) uniquely associates with proinflammatory HDL in atherogenic mice and coronary heart disease (CHD) patients. In this paper, we report that Hb and its scavenger proteins, haptoglobin (Hp) and hemopexin (Hx) are significantly increased in apoA-1-containing particles of HDL both in mouse models of hyperlipidemia and in CHD patients, when compared with wild type mice and healthy donors, respectively. We further demonstrate that the association of Hb, Hp, and Hx proteins with HDL positively correlates with inflammatory properties of HDL and systemic inflammation in CHD patients. Interestingly, HDL from Hp(-/-) mice under atherogenic conditions does not accumulate Hb and is anti-inflammatory, suggesting that (i) Hp is required for the association of Hb with HDL and (ii) Hb x Hp complexes regulate the inflammatory properties of HDL. Moreover, treatment of apoE(-/-) mice with an apoA-1 mimetic peptide resulted in significant dissociation of Hb x Hp complexes from HDL and improvement of HDL inflammatory properties. Our data strongly suggest that HDL can become proinflammatory via the Hb x Hp pathway in mice and humans, and dissociation of Hb x Hp x Hx complexes from apoA-1-containing particles of HDL may be a novel target for the treatment of CHD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19433579      PMCID: PMC2709397          DOI: 10.1074/jbc.M109.017202

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  52 in total

1.  On evolutionary biology, inflammation, infection, and the causes of atherosclerosis.

Authors:  Paul M Ridker
Journal:  Circulation       Date:  2002-01-01       Impact factor: 29.690

2.  Estradiol esterification in the human preovulatory follicle.

Authors:  L Cigliano; M S Spagnuolo; B Dale; M Balestrieri; P Abrescia
Journal:  Steroids       Date:  2001-12       Impact factor: 2.668

Review 3.  HDL and the inflammatory response induced by LDL-derived oxidized phospholipids.

Authors:  M Navab; J A Berliner; G Subbanagounder; S Hama; A J Lusis; L W Castellani; S Reddy; D Shih; W Shi; A D Watson; B J Van Lenten; D Vora; A M Fogelman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-04       Impact factor: 8.311

Review 4.  The oxidative modification hypothesis of atherosclerosis: does it hold for humans?

Authors:  J L Witztum; D Steinberg
Journal:  Trends Cardiovasc Med       Date:  2001 Apr-May       Impact factor: 6.677

5.  Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3.

Authors:  M Navab; S Y Hama; G M Anantharamaiah; K Hassan; G P Hough; A D Watson; S T Reddy; A Sevanian; G C Fonarow; A M Fogelman
Journal:  J Lipid Res       Date:  2000-09       Impact factor: 5.922

6.  A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids.

Authors:  M Navab; S Y Hama; G P Hough; G Subbanagounder; S T Reddy; A M Fogelman
Journal:  J Lipid Res       Date:  2001-08       Impact factor: 5.922

7.  High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection.

Authors:  B J Van Lenten; A C Wagner; D P Nayak; S Hama; M Navab; A M Fogelman
Journal:  Circulation       Date:  2001-05-08       Impact factor: 29.690

8.  Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment.

Authors:  Benjamin J Ansell; Mohamad Navab; Susan Hama; Naeimeh Kamranpour; Gregg Fonarow; Greg Hough; Shirin Rahmani; Rachel Mottahedeh; Ravi Dave; Srinivasa T Reddy; Alan M Fogelman
Journal:  Circulation       Date:  2003-11-24       Impact factor: 29.690

9.  Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis.

Authors:  Katherine R Kozak; Malaika W Amneus; Suzanne M Pusey; Feng Su; Mui N Luong; Sam A Luong; Srinivasa T Reddy; Robin Farias-Eisner
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-01       Impact factor: 11.205

10.  Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype.

Authors:  Rabea Asleh; Shany Blum; Shiri Kalet-Litman; Jonia Alshiek; Rachel Miller-Lotan; Roy Asaf; Wasseem Rock; Michael Aviram; Uzi Milman; Chen Shapira; Zaid Abassi; Andrew P Levy
Journal:  Diabetes       Date:  2008-07-03       Impact factor: 9.461

View more
  56 in total

1.  A biochemical fluorometric method for assessing the oxidative properties of HDL.

Authors:  Theodoros Kelesidis; Judith S Currier; Diana Huynh; David Meriwether; Christina Charles-Schoeman; Srinivasa T Reddy; Alan M Fogelman; Mohamad Navab; Otto O Yang
Journal:  J Lipid Res       Date:  2011-09-27       Impact factor: 5.922

2.  Identification of hemopexin as an anti-inflammatory factor that inhibits synergy of hemoglobin with HMGB1 in sterile and infectious inflammation.

Authors:  Tian Lin; Fatima Sammy; Huan Yang; Sujatha Thundivalappil; Judith Hellman; Kevin J Tracey; H Shaw Warren
Journal:  J Immunol       Date:  2012-07-06       Impact factor: 5.422

3.  Serum amyloid A in uremic HDL promotes inflammation.

Authors:  Thomas Weichhart; Chantal Kopecky; Markus Kubicek; Michael Haidinger; Dominik Döller; Karl Katholnig; Cacang Suarna; Philipp Eller; Markus Tölle; Christopher Gerner; Gerhard J Zlabinger; Markus van der Giet; Walter H Hörl; Roland Stocker; Marcus D Säemann
Journal:  J Am Soc Nephrol       Date:  2012-01-26       Impact factor: 10.121

4.  Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer.

Authors:  Feng Su; Kathy R Kozak; Satoshi Imaizumi; Feng Gao; Malaika W Amneus; Victor Grijalva; Carey Ng; Alan Wagner; Greg Hough; Gina Farias-Eisner; G M Anantharamaiah; Brian J Van Lenten; Mohamad Navab; Alan M Fogelman; Srinivasa T Reddy; Robin Farias-Eisner
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-01       Impact factor: 11.205

Review 5.  Haptoglobin genotype and its role in diabetic cardiovascular disease.

Authors:  Tina Costacou; Andrew P Levy
Journal:  J Cardiovasc Transl Res       Date:  2012-03-24       Impact factor: 4.132

Review 6.  HDL and cholesterol: life after the divorce?

Authors:  Kasey C Vickers; Alan T Remaley
Journal:  J Lipid Res       Date:  2013-03-19       Impact factor: 5.922

7.  Featured Article: Depletion of HDL3 high density lipoprotein and altered functionality of HDL2 in blood from sickle cell patients.

Authors:  Eric Soupene; Sandra K Larkin; Frans A Kuypers
Journal:  Exp Biol Med (Maywood)       Date:  2017-04-24

8.  An in vivo drug screening model using glucose-6-phosphate dehydrogenase deficient mice to predict the hemolytic toxicity of 8-aminoquinolines.

Authors:  Peng Zhang; Xiugong Gao; Hiroshi Ishida; Jack Amnuaysirikul; Peter J Weina; Max Grogl; Michael T O'Neil; Qigui Li; Diana Caridha; Colin Ohrt; Mark Hickman; Alan J Magill; Prabhati Ray
Journal:  Am J Trop Med Hyg       Date:  2013-03-25       Impact factor: 2.345

Review 9.  High-density lipoprotein and 4F peptide reduce systemic inflammation by modulating intestinal oxidized lipid metabolism: novel hypotheses and review of literature.

Authors:  Mohamad Navab; Srinivasa T Reddy; Brian J Van Lenten; Georgette M Buga; Greg Hough; Alan C Wagner; Alan M Fogelman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-11       Impact factor: 8.311

Review 10.  HDL as a biomarker, potential therapeutic target, and therapy.

Authors:  Mohamad Navab; G M Anantharamaiah; Srinivasa T Reddy; Brian J Van Lenten; Alan M Fogelman
Journal:  Diabetes       Date:  2009-12       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.